Literature DB >> 7977053

Effects of octreotide on left ventricular mass in acromegaly.

S L Tokgözoğlu1, T Erbaş, K Aytemir, S Akalin, S Kes, E Oram.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7977053     DOI： 10.1016/0002-9149(94)90865-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  9 in total

Review 1.  Improvement of cardiac parameters in patients with acromegaly treated with medical therapies.

Authors:  Annamaria Colao
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

Review 2.  Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.

Authors:  J C Gillis; S Noble; K L Goa
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

3.  Short term reduction of left ventricular mass in primary hypertrophic cardiomyopathy by octreotide injections.

Authors:  A I Günal; A Işik; H Celiker; O Eren; H Celebi; S Y Günal; C Lüleci
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

4.  The GH/IGF-1 Axis and Heart Failure.

Authors:  Graziella Castellano; Flora Affuso; Pasquale Di Conza; Serafino Fazio
Journal:  Curr Cardiol Rev       Date:  2009-08

5.  The treatment of de novo acromegalic patients with octreotide-LAR: efficacy, tolerability and cardiovascular effects.

Authors:  J Gilbert; M Ketchen; P Kane; T Mason; E Baister; M Monaghan; S Barr; P E Harris
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

6.  Effect of growth hormone treatment on diastolic function in patients who have developed growth hormone deficiency after definitive treatment of acromegaly.

Authors:  Pouneh K Fazeli; Jonathan G Teoh; Eleanor L Lam; Anu V Gerweck; Tamara L Wexler; Eliza P Teo; Brian M Russell; Ronen Durst; David McCarty; Rory B Weiner; Michael H Picard; Anne Klibanski; Karen K Miller
Journal:  Growth Horm IGF Res       Date:  2015-12-03       Impact factor: 2.372

7.  Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study.

Authors:  G Lombardi; A Colao; P Marzullo; B Biondi; E Palmieri; S Fazio
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

Review 8.  Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.

Authors:  Kate McKeage; Susan Cheer; Antona J Wagstaff
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Effects of somatostatin analog treatment on cardiovascular parameters in patients with acromegaly: A systematic review.

Authors:  Maryam Heidarpour; Davood Shafie; Ashraf Aminorroaya; Nizal Sarrafzadegan; Ziba Farajzadegan; Rasool Nouri; Arash Najimi; Christina Dimopolou; Gunter Stalla
Journal:  J Res Med Sci       Date:  2019-04-26       Impact factor: 1.852
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.